BMY
Price
$47.14
Change
+$0.45 (+0.96%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
95.95B
55 days until earnings call
NVS
Price
$129.74
Change
+$1.32 (+1.03%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
250.37B
53 days until earnings call
Interact to see
Advertisement

BMY vs NVS

Header iconBMY vs NVS Comparison
Open Charts BMY vs NVSBanner chart's image
Bristol-Myers Squibb
Price$47.14
Change+$0.45 (+0.96%)
Volume$55.11K
Capitalization95.95B
Novartis AG
Price$129.74
Change+$1.32 (+1.03%)
Volume$6.14K
Capitalization250.37B
BMY vs NVS Comparison Chart in %
Loading...
BMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BMY vs. NVS commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a StrongBuy and NVS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (BMY: $46.69 vs. NVS: $128.42)
Brand notoriety: BMY: Notable vs. NVS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BMY: 91% vs. NVS: 93%
Market capitalization -- BMY: $95.95B vs. NVS: $250.37B
BMY [@Pharmaceuticals: Major] is valued at $95.95B. NVS’s [@Pharmaceuticals: Major] market capitalization is $250.37B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $651.91B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $90.72B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMY’s FA Score shows that 2 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).

  • BMY’s FA Score: 2 green, 3 red.
  • NVS’s FA Score: 3 green, 2 red.
According to our system of comparison, NVS is a better buy in the long-term than BMY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMY’s TA Score shows that 6 TA indicator(s) are bullish while NVS’s TA Score has 6 bullish TA indicator(s).

  • BMY’s TA Score: 6 bullish, 4 bearish.
  • NVS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NVS is a better buy in the short-term than BMY.

Price Growth

BMY (@Pharmaceuticals: Major) experienced а -0.41% price change this week, while NVS (@Pharmaceuticals: Major) price change was +1.54% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.01%. For the same industry, the average monthly price growth was +3.85%, and the average quarterly price growth was +10.24%.

Reported Earning Dates

BMY is expected to report earnings on Oct 30, 2025.

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.01% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVS($250B) has a higher market cap than BMY($96B). BMY (18.93) and NVS (18.72) have similar P/E ratio . NVS YTD gains are higher at: 36.721 vs. BMY (-14.522). NVS has higher annual earnings (EBITDA): 22.7B vs. BMY (15.1B). BMY has more cash in the bank: 13.6B vs. NVS (7B). NVS has less debt than BMY: NVS (32.6B) vs BMY (50.9B). NVS has higher revenues than BMY: NVS (55.2B) vs BMY (47.7B).
BMYNVSBMY / NVS
Capitalization96B250B38%
EBITDA15.1B22.7B67%
Gain YTD-14.52236.721-40%
P/E Ratio18.9318.72101%
Revenue47.7B55.2B86%
Total Cash13.6B7B194%
Total Debt50.9B32.6B156%
FUNDAMENTALS RATINGS
BMY vs NVS: Fundamental Ratings
BMY
NVS
OUTLOOK RATING
1..100
1526
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
14
Undervalued
PROFIT vs RISK RATING
1..100
10012
SMR RATING
1..100
3329
PRICE GROWTH RATING
1..100
5948
P/E GROWTH RATING
1..100
4680
SEASONALITY SCORE
1..100
n/a65

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMY's Valuation (6) in the Pharmaceuticals Major industry is in the same range as NVS (14). This means that BMY’s stock grew similarly to NVS’s over the last 12 months.

NVS's Profit vs Risk Rating (12) in the Pharmaceuticals Major industry is significantly better than the same rating for BMY (100). This means that NVS’s stock grew significantly faster than BMY’s over the last 12 months.

NVS's SMR Rating (29) in the Pharmaceuticals Major industry is in the same range as BMY (33). This means that NVS’s stock grew similarly to BMY’s over the last 12 months.

NVS's Price Growth Rating (48) in the Pharmaceuticals Major industry is in the same range as BMY (59). This means that NVS’s stock grew similarly to BMY’s over the last 12 months.

BMY's P/E Growth Rating (46) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVS (80). This means that BMY’s stock grew somewhat faster than NVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BMYNVS
RSI
ODDS (%)
Bullish Trend 3 days ago
32%
Bearish Trend 2 days ago
38%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
54%
Bearish Trend 2 days ago
37%
Momentum
ODDS (%)
Bearish Trend 2 days ago
59%
Bullish Trend 2 days ago
48%
MACD
ODDS (%)
Bearish Trend 2 days ago
45%
Bullish Trend 2 days ago
52%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
53%
Bullish Trend 2 days ago
49%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
52%
Bullish Trend 2 days ago
46%
Advances
ODDS (%)
Bullish Trend 3 days ago
53%
Bullish Trend 2 days ago
49%
Declines
ODDS (%)
Bearish Trend 12 days ago
54%
Bearish Trend about 1 month ago
45%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
52%
Bearish Trend 2 days ago
47%
Aroon
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
41%
View a ticker or compare two or three
Interact to see
Advertisement
BMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FNDX25.890.22
+0.86%
Schwab Fundamental U.S. Large CompanyETF
GGN4.820.02
+0.42%
GAMCO Global Gold Natural Resources & Income Trust
SSFI21.610.07
+0.33%
Day Hagan Smart Sector Fixed Income ETF
HYXF47.390.11
+0.23%
iShares ESG Advanced Hi Yld Corp Bd ETF
XIJN30.910.03
+0.11%
FT Vest U.S. Eq Bffr & Prm Inc ETF -June

BMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMY
1D Price
Change %
BMY100%
-1.71%
PFE - BMY
53%
Loosely correlated
-1.01%
GILD - BMY
47%
Loosely correlated
-0.19%
MRK - BMY
46%
Loosely correlated
-0.15%
AMGN - BMY
45%
Loosely correlated
-1.32%
NVS - BMY
45%
Loosely correlated
+0.15%
More

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+0.15%
GSK - NVS
68%
Closely correlated
+0.64%
AZN - NVS
61%
Loosely correlated
-0.40%
PFE - NVS
57%
Loosely correlated
-1.01%
JNJ - NVS
54%
Loosely correlated
+0.43%
SNY - NVS
54%
Loosely correlated
-9.14%
More